Try our corporate solution for free!
+1 (212) 419-5770

Market share of top 20 companies for orphan drugs worldwide 2018 and 2024

Among companies that marketed orphan drugs in 2018, Celgene held the largest percentage of the orphan drug market at that time. It is projected that by 2024 Celgene will still hold the largest percentage of the orphan drug market but significantly less than in 2018. Celgene's orphan drug market share in 2018 was nearly 10 percent, but until 2024, the company's orphan drug market share is expected to drop to 5.6 percent. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.

Ophan drugs overview

Orphan drugs are pharmaceutical products designed to help treat, prevent and even diagnose extremely rare disorders and disease. A rare disease and disorder is defined as an illness that affects 1 in 2,000 people (in Europe) or one that affects less than 200,000 individuals (in the U.S.). The top orphan drug based on revenue in 2018 was Revlimid. It is a drug used to treat certain types of cancers and genetic disorders. It is projected that by 2024 the top orphan drug, by revenue, will be Imbruvica (ibrutinib).

The orphan drug market

The number of orphan drugs on the market in the U.S. had increased dramatically over the last two decades. There were over 460 drugs with an orphan distinction in the U.S. during 2017. Orphan drugs are typically significantly more expensive than non-orphan drugs. The average per patient cost of an orphan drug in the U.S. is about 4.5 times as expensive as a non-orphan drug. Despite the cost and the number of drugs available, the global orphan drug market has experienced varying degrees of growth. Data indicates that, while there will still be revenue growth in the future, the percentage of growth will begin to decline or remain stable.

Top 20 pharmaceutical companies worldwide by orphan drug revenue market share in 2024 compared to 2018*

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until October 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

April 2019



Survey time period

as of April 2019

Supplementary notes

* Products that have orphan and non-orphan drug designations and are expected to generate less than 50% of their sales in 2018 and 2024 from their orphan-designated indication/s, are excluded from this statistic. This has led to the exclusion of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade.
** Forecast.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Orphan drugs"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.